Using progestin on treating endometrial hyperplasia

A prospective study was performed on 72 endometrial hyperplasia patients who had been treated by progestin from 2000 - 2004. Results: After 3-6 months of the treatment, there were 57 patients recovered completely (79.16%); 10 patients had hysterectomy because of unsuccessful treatment, these patients had uterus polyp, leiomyoma, long bleeding unrespond to treatment; 1 case was defined endometrial cancer afterward. 3 patients had endometrial hyperplasia in endometrial biopsy after 6 months of intensive treatment. Using of progestin in treating endometrial hyperplasia needs an accurate pathological diagnosis of endometrial diseases, the cooperation of doctors and a regular follow- up. Women with endometrial hyperplasia who were treated with progestin had uterus preserved therefore their menstruation became regularly after recovering and; several young women even got pregnant and become a mother.

Distribution of congenital birth defects and the value of early diagnosis using ultrasound at the National hospital of obstetries and gynecology during 3 years from 2001 to 2003

Ultrasound (US) is currently contributing to early detection of congenital birth defects (CBDs) but its diagnostic value is not yet systemically assessed. Objectives: To describe the distribution of CBDs among children born at the National Hospital of Obstetrics and Gynecology from 2001 to 2003 and to assess the effectiveness and diagnostic value of US. Methods: A descriptive cross-sectional study involving all mothers and their fetuses/newborns with CBDs at the NHOG from Jan 2001 to Dec 2003. Results: The number of fetuses with CBDs detected during the 3 years was 933, accounted for 2.7%. CBDs of the central nervous system and the head-face-neck area accounted for 36.2%; followed by abdominal organs (33.0%), bones and extremities (17.0%), thorax (9.0%) and others. The percentage of CBDs detected at gestational age from 12 to 23 weeks has increased two-fold from 2001 to 2003. Conclusions: The percentage of CBDs detected during the 3 years was 2.7%, with CBDs of the central nervous system and the head-face-neck area accounted for 36.2%; followed by abdominal organs (33.0%), bones and extremities (17.0%), thorax (9.0%). US played the 1st role leading to suspicion of CBDs (39.7%). For fetuses less than 32 weeks, 2-D and 3-D US have diagnostic values of more than 97%.